1. Home
  2. NP vs TLX Comparison

NP vs TLX Comparison

Compare NP & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NP

Neptune Insurance Holdings Inc.

HOLD

Current Price

$25.08

Market Cap

3.9B

Sector

Finance

ML Signal

HOLD

Logo Telix Pharmaceuticals Limited American Depositary Shares

TLX

Telix Pharmaceuticals Limited American Depositary Shares

HOLD

Current Price

$9.16

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NP
TLX
Founded
2017
2015
Country
United States
Australia
Employees
60
1184
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NP
TLX
Price
$25.08
$9.16
Analyst Decision
Buy
Strong Buy
Analyst Count
12
4
Target Price
$28.17
$21.13
AVG Volume (30 Days)
864.9K
98.2K
Earning Date
04-22-2026
08-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$25.84
N/A
Revenue Next Year
$15.80
N/A
P/E Ratio
N/A
$150.33
Revenue Growth
N/A
N/A
52 Week Low
$14.78
$6.28
52 Week High
$31.75
$18.13

Technical Indicators

Market Signals
Indicator
NP
TLX
Relative Strength Index (RSI) 42.00 34.04
Support Level $24.16 $8.85
Resistance Level $26.85 $9.92
Average True Range (ATR) 1.46 0.23
MACD -0.32 -0.16
Stochastic Oscillator 10.25 1.11

Price Performance

Historical Comparison
NP
TLX

About NP Neptune Insurance Holdings Inc.

Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Share on Social Networks: